Urology
Volume 72, Issue 6 , Pages 1214-1218 , December 2008

Pathologic T2 Stage Subgroups and Recurrence-Free Survival After Radical Prostatectomy

Received 29 August 2007 ,Accepted 21 January 2008.

References 

  1. Mackillop WJ, O'Sullivan B, Gospodarowicz M. The role of cancer staging in evidence-based medicine. Cancer Prev Control. 1998;2:269–277
  2. Beahrs OH, Henson DE, Hutter RVP, et al. American Joint Committee on Cancer Staging Manual. Philadelphia: Lippincott; 1992;pp 181–186
  3. Fleming ID, Cooper JS, Henson DE, et al. American Joint Committee on Cancer Staging Manual. Philadelphia: Lippincott; 1997;pp 219–222
  4. Cagiannos I, Graefen M, Karakiewicz PI, et al. Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement?. J Clin Oncol. 2002;20:2025–2030
  5. Han M, Walsh PC, Partin AW, et al. Ability of the 1992 and 1997 American Joint Committee on cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease. J Urol. 2000;164:89–92
  6. Stamey TA, Sozen TS, Yemoto CM, et al. Classification of localized untreated prostate cancer based on 791 men treated only with radical prostatectomy: common ground for therapeutic trials and TNM subgroups. J Urol. 1998;159:2009–2012
  7. Greene F. American Joint Committee on Cancer Staging Manual. New York: Springer-Verlag; 2002;pp 308–314
  8. Banerjee M, Biswas D, Sakr W, et al. Recursive partitioning for prognostic grouping of patients with clinically localized prostate carcinoma. Cancer. 2000;89:404–411
  9. Han H, Partin AW, Zahurak A, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517–523
  10. Quinn DI, Henshall SM, Haynes AM, et al. Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J Clin Oncol. 2001;19:3692–3705
  11. Lau WK, Bergstralh EJ, Blute ML, et al. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol. 2002;167:117–122
  12. Ung JO, Richie JP, Chen MH, et al. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology. 2002;60:458–463
  13. Ramos CG, Roehl KA, Antenor JV, et al. Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer. J Urol. 2004;172:137–140
  14. Hutter RV, Montie JE, Busch C, et al. Current prognostic factors and their relevance to staging. Cancer. 1996;78:369–371
  15. Renshaw AA, Richie JP, Loughlin KR, et al. The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens. Cancer. 1998;85:1208–1210

PII: S0090-4295(08)00135-0

doi: 10.1016/j.urology.2008.01.054

Urology
Volume 72, Issue 6 , Pages 1214-1218 , December 2008

Article Tools

* Image Usage & Resolution